Loading video...

Video Failed to Load

Go Home

The Visible Human Project 2.0: Advancing Anatomical Visualization The NLM Visible Human Project has created publicly available, anatomically detailed, 3D representations of both male and female bodies. This initiative continues to push the boundaries of medical imaging and education. One notable dataset features a 72-year-old male donor, meticulously preserved...

19,060 views • 1 year ago •via X (Twitter)

3 Comments

Raffaele Di Giacomo, PhD's profile picture
Raffaele Di Giacomo, PhD1 year ago

The Visible Human Project 2.0 is indeed a fascinating step forward in medical imaging and anatomical study. These detailed 3D representations can revolutionize how medical students and professionals understand the human body's intricacies. How do you see this influencing medical education and research in the future? #Medicine For an in-depth look at biomedical advancements, visit This platform offers comprehensive reviews and answers to every biomedical question. Support Medical Doctors in Uganda: Help by sharing this GoFundMe! 🙏 ❤️ →

AdvancingDialysis.org's profile picture
AdvancingDialysis.org1 year ago

See the data: PD could be a better approach for unplanned, new-to-dialysis patients compared to in-center hemodialysis. // #PeritonealDialysis #QualityofLife #Hemodialysis

Dr. Hemalatha Ramachandran's profile picture
Dr. Hemalatha Ramachandran1 year ago

@AlexandraCzap @AmeerEHassan @caseyalbin @AshuPJadhav @_AdnanSiddiqui @adnan_mujanovic @NguyenThanhMD @DGlaucomflecken @dyavagal @elghanemmoh That's amazing!! Visible Human Project continues to influence medical imaging and education!

Related Videos

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution

Dr. Filippo Cademartiri

11,820 views • 1 year ago

I am very pleased to announce that I will be stepping down as President of the Ontario Association of Radiologists and moving into the role of Chair of the Board. Over my years as president we've seen medical imaging and interventional radiology rapidly progress in Ontario. Last year alone, the Ford government introduced 49 new MRI units into hospitals across the province. This year we'll see the rollout of private delivery of publicly funded MRI and CT outpatient facilities through Bill 60. This coming year, in partnership with the Ford government, we hope to expand vertebroplasty services allowing for quick and effective treatment of osteoporotic vertebral body fractures for seniors across Ontario. In partnership with Sheridan College and the Ford government, we hope to see the roll out of a new Medical Radiation Technologist training program to serve our growing health human resources needs. My most cherished project however has been reducing the age of breast cancer screening from 50 down to 40 years of age. This will save many young lives. I want to thank Minister Sylvia Jones and Premier Doug Ford for taking great interest in this project. It is deeply meaningful to me. I wish my friend and colleague Dr. Mark Baerlocher great success as he takes over the role this coming year. His good humor and clinical excellence will serve the province and the association well. Thank you all for your support and encouragement over the last 5 years. I will continue to work quietly in the background to ensure the ongoing development and success of medical imaging and interventional radiology in our great province.

David Jacobs

60,895 views • 1 year ago

We’re thrilled to share that our MERFISH+ preprint is now live on bioRxiv!👉 In this work, the Bintu and Zhu labs (UCSD) developed MERFISH+, a next-generation spatial genomics platform that combines genome-wide RNA and epigenetic imaging over a large field of view. By introducing acrydite-modified probes covalently anchored to hydrogels, MERFISH+ achieves remarkable imaging stability and enables >1,800-gene, multi-modal, and multi-month experiments. With this platform, they, together with the Chi lab at UCSD, profiled a whole developing human heart at 12 post-conception week with merely two slides, resulting in a total of 53 slides, 3.1 million single cells and more than 30 cell types. Building upon our previous 3D reconstruction and modeling framework, Spateo ( we reconstruct the 3D human heart that nicely captures the anatomical structure of the heart, including the intricate vasculature network. Sophisticated analyses provide a holistic view of an entire organ and enable systematic characterization of 3D cellular neighborhoods and transcriptional gradients of substructures such as the descending arteries. Furthermore, using a generative integration framework for spatial multimodal data (Spateo-VI), we harmonized these MERFISH+ transcriptomic and chromatin data to reconstruct a 3D spatially-resolved multi-omics atlas of the developing human heart, shared at and MERFISH+ thus sets a new standard for large-format, multi-omic spatial profiling, enabling holistic, 3D characterization of organs at subcellular resolution. Huge congratulations to first authors Colin Kern, qingquan Zhang, Yifan Lu , and Jacqueline Eschbach, and to all collaborators from the Bintu, Zhu, Chi, and Qiu labs for this amazing team effort. Thanks for your diligence, creativity, and hard work on this project. We’re grateful for support from Arc Institute and our generous donors. Our lab is expanding—if you’re excited about building the next generation of single-cell and spatial genomics techniques and predictive single cell and spatial foundation models, we’re hiring! If you are interested, please reach out to me via direct message or email at [email protected]. We are excited for any potential collaborations along this line of research in Stanford, UCSF and Berkeley and other labs as well.

evo-devo

42,166 views • 8 months ago

Dr Anthony Fauci authorized over $200 million US taxpayer dollars for transgender animal testing and animal torture “Can you describe what exactly the American people's taxpayer dollars were spent on regarding transgender animal testing?” “Yeah: - In a lot of these cases, they involve mice, rats, monkeys who are being surgically mutilated and subjected to hormone therapies to mimic female to male or male to female gender transitions - Gender affirming hormone therapies, and then looking at the biological, psychological, and physiological effects of the gender transitions - Looking at the effects of taking vaccines after you've transitioned these animals from male to female or female to male - Looking at the size of their genitals changing after you've put them on estrogen or testosterone therapies to transition them - There was a $1.1 million grant to give female lab rats testosterone to mimic transgender male humans and then overdose them with this party drug to see if female animals taking testosterone were more likely to overdose on the sex party drug than animals who are not taking testosterone “Are many of these taxpayer funded animal studies shared with the public or is there a significant oversight of this research?” “You essentially needed a degree in information technology to navigate the federal spending databases to find any of this stuff.” “In our analysis, Dr. Fauci funded about 95% of the change-drender animal experiments” “What we are doing to test human effects is poisoning lab animals - Forcing them to breathe wildfire smoke simulated in a laboratory by burning different types of foliage and pumping into animals cages - Making them obese to simulate what it would be like for obese people to be exposed to wildfire smoke - Shooting off handguns and rifles and forcing animals to breathe the emissions and gun control experiments - and the list goes on and on”

Wall Street Apes

237,297 views • 1 year ago

After acquiring the popular Rapour Hotels at Amakohia Layout, Off Orlu Road, by Rapour junction, Owerri, Imo State, Nigeria, for expansion and following the launch of its HIV Prevention Programme, Mark Of Glory Specialist Hospital has unveiled The Surgical Room, a new educational medical series designed to inspire aspiring and practicing medical professionals. Located at No. 30 MCC Road, between former ITC and TRACAS Parks, Owerri, Imo State, Mark Of Glory Specialist Hospital continues to strengthen its presence in healthcare delivery, medical education, and public awareness following its acquisition of the popular Rapour Hotels in Owerri as part of its expansion plans. The Surgical Room explores various medical conditions, diagnoses, and surgical procedures used in their treatment. Designed with a cinematic approach, the series combines medical education with storytelling, making complex medical concepts easier to understand. According to the Chairman of the Management Board, Dr. Mark Okhueleigbe, a neurosurgeon based in Owerri, the project was conceived as an educational tool to encourage young men and women pursuing careers in medicine while also serving as a source of inspiration and learning for healthcare professionals. Speaking on the initiative, Osawele Emmanuel, Head of Narrative Media MOGSH, stated that appointments can be conveniently booked through the hospital's official website, Known for its high success rate in managing critical cases and its culture of medical innovation and excellence, Mark Of Glory Specialist Hospital continues to advance healthcare excellence under its slogan: "We Love and Care for You." Watch The Surgical Room and follow Narrative Media MOGSH: YouTube: X (Twitter): Book appointments and learn more:

Instablog9ja

42,405 views • 16 days ago

🚨BREAKING: Yale researchers assess RSF carried out systematic mass killings in El-Fasher and then destroyed the evidence, according to a new report by the Yale School of Public Health’s Humanitarian Research Lab, published Dec. 16. Based on satellite imagery, Yale HRL says it has high confidence that the Rapid Support Forces carried out widespread mass killings after seizing full control of El-Fasher, North Darfur on Oct. 26, 2025, targeting civilians attempting to flee and those sheltering in Daraja Oula, the city’s last major civilian refuge. Researchers identified at least 150 clusters - piles of human remains - visible between Oct. 26 and Nov. 1. By Nov. 28, 72% of those clusters had changed in size, with 38% no longer visible, consistent with a coordinated effort to bury, burn, or remove bodies. Yale also documented reddish discoloration consistent with blood, RSF-linked vehicle activity near dozens of sites, and signs of burning and disturbed earth. No evidence of civilian burial practices was found. The distribution points to four patterns: killings of civilians fleeing the city, door-to-door and execution-style killings in Daraja Oula, killings linked to detention or filtration sites, and killings at military installations. Yale concluded no alternative explanation accounts for the scale, timing, and consistency of the findings. 🎥 Executive Director Nathaniel Raymond Nathaniel Raymond detailed the latest findings to Drop Site this morning.

Drop Site

27,690 views • 7 months ago